Glucagon’s Role: A Technical Pros and Cons Analysis
Glucagon’s Role: A Technical Pros and Cons Analysis Glucagon, a 29-amino acid peptide hormone, primarily counteracts hypoglycemia by stimulating hepatic glycogenolysis and gluconeogenesis. Pros: It offers rapid rescue in severe hypoglycemia (elevating blood glucose by 30-50 mg/dL within 10 minutes) and is used in diagnostic gastrointestinal imaging. Cons: Its short half-life ( 3-6 minutes) limits therapeutic stability; adverse effects include nausea (20-30% incidence) and rebound hyperglycemia. In the peptide market (projected CAGR 8.2% through 2030), glucagon analogs (e.g., dasiglucagon) improve stability via non-native amino acid substitutions. Brand comparisons (e.g., GlucaGen vs. Baqsimi) highlight nasal vs. injectable delivery trade-offs. Technical limitations include poor solubility and aggregation, driving R&D in formulation (e.g., lyophilized powders). Regulatory certifications (FDA, EMA) ensure purity >95%. For selection, prioritize stability data and cold-chain logistics (2-8°C). Market trends favor dual-action GLP-1/glucagon agonists for obesity.